2014-04-15 14:53:09 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Shanghai Shenqi Pharmactcl Inv Mgt CoLtd (600613) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Shanghai Shenqi Pharmactcl Inv Mgt CoLtd (600613). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Shanghai Shenqi Pharmactcl Inv Mgt CoLtd investor.
Report Summary: Shanghai Shenqi Pharmactcl Inv Mgt CoLtd is an above average quality company with a positive outlook. Shanghai Shenqi Pharmactcl Inv Mgt CoLtd has strong business growth and is run by efficient management. The trend in Shanghai Shenqi Pharmactcl Inv Mgt CoLtd fair value exchange rate against its closest rated-competitor, Renhe Pharmacy Co., Ltd., has been depreciating over the past 2 weeks. When compared to its closest competitor, Shanghai Shenqi Pharmactcl Inv Mgt CoLtd
shows similar undervaluation and is equally likely to underperform the market.
The report breaks down the Total StockMark into its three components - business, management and price, performing an in-depth analysis of Shanghai Shenqi Pharmactcl Inv Mgt CoLtd for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext and from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, One source West Services, and Dow Jones/Factiva.
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering 31 different markets and over 22,000 companies. The StockMarks rating system is based on proven investment principles and is designed to drive long-term shareholder returns.